Biostem, Inc. Benchmark Coverage To Be Initiated By Investrend Research.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- (Investrend Research Syndicate) Biostem Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BTEM) has enrolled in the unique shareholder empowerment platform administered by Investrend Communications, Inc., a provider of financial intelligence programs. Benchmark research coverage will be initiated by Investrend Research analyst Daniel Capo, CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. . Investrend Research is located on the web at http://www.investrendresearch.com , and the analysts' qualifications are at http://www.investrend.com/articles/secondlevel.asp?level=238 . Biostem has announced it is acquiring Cryobanks International, Inc., a leader in the collection, processing, and banking of stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young derived from the umbilical cord umbilical cord (ŭmbĭl`ĭkəl), cordlike structure about 22 in. (56 cm) long in the pregnant human female, extending from the abdominal wall of the fetus to the placenta. immediately after birth, with a current unrelated (for transplant) cord blood bank A cord blood bank is a facility which stores umbilical cord blood for future use. Cord blood, a precious resource physiologically tranfused from the placenta through the umbilical cord to the neonate for stabilization upon birth, is not recommended to be harvested for the vast inventory of over 8,500 units, plus over 1,000 research units. Cryobanks is engaged in three core businesses. The first is the collection and storage of Cord Blood cord blood n. Blood present in the umbilical vessels at the time of delivery. units donated by the parents at birth for unrelated cord blood transplants worldwide. Cryobanks also collects Cord Blood units for personal storage, to be used, if necessary, by the donor family or its designees. In this case, the donating family pays for collection, processing and storage, plus an annual fee for continued storage. Cryobanks International has approximately 2,000 of these units stored. The third involves technology licensing with an existing agreement in Greece, seven in various stages of development in India and over 20 other requests. Cryobanks will also use donated cord blood units for research purposes, and expects to help sponsor research in areas related to stem cell therapy stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs , and has entered into or is currently negotiating several research projects. Cryobanks strives to be the leading bank for stored Cord Blood in the world. The company does not use stem cells derived from fetal (embryonic) tissue and is therefore not subject to the many ethical and emotional issues surrounding fetal stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. research. Cryobanks uses only stem cells obtained from umbilical cords. The company's website is at http://www.cryo-intl.com An InvestorPower(TM) page has been created regarding the company at http://www.investrend.com/company/list.asp?sPathParam=yes. Investrend Research has been the leading independent equity research publishing and distribution program since 1996, with over 75 qualified professional analysts posting more than 1,000 reports to date. Anyone may enroll a company. Enrollment fees for the Benchmark research platform are $24,800, which are being paid by Equities Magazine, a third party. Analysts are paid in advance for their initial reports by Investrend Research to limit or eliminate pecuniary interests, and no one associated with the program may own or trade in the equities of companies under coverage. The company's research has also been enrolled in the investor-monitoring program by the Shareholders Research Alliance (http://www.shareholdersresearch.com), established to eliminate conflict and bias, and Investrend subscribes to the exacting "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com. Anyone interested in receiving alerts regarding Biostem research or webcasts should e-mail contact@investrend.com with "BTEM" in the subject line, or click on http://www.investrend.com/contact.asp. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion